Skip to main content

Table 4 MSI status in relation to the expression of hMSH2, hMLH1, and p53 protein

From: Microsatellite instability at a tetranucleotide repeat in type I endometrial carcinoma

 

IHC

No.

MSS

MSI-H

EMAST

p-value

hMSH2

Positive

30

15(92.8%)

3(37.5%)

12(80.0%)

0.01

 

Negative

9

1(7.2%)

5(62.5%)

3(20.0%)

 

hMLH1

Positive

31

16(100.0%)

2(33.3%)

13(86.7%)

<0.01

 

Negative

8

0(0.0%)

6(66.7%)

2(13.3%)

 

hMSH2 and hMLH1

Positive, both

26

15(93.7%)

1(12.5%)

10(67.7%)

<0.01

 

Negative, at least one

13

1(6.3%)

7(87.5%)

5(33.3%)

 

p53

+

13

5(31.3%)

1(12.5%)

7(46.7%)

0.25

 

-

26

11(68.7%)

7(87.5%)

8(53.3%)

 

Total

 

39

16

8

15

 
  1. IHC : Immunohistochemistry.
  2. MSS : Microsatellite stable.
  3. MSI : Microsatellite instability – high frequency.
  4. EMAST : Elevated microsatellite alterations at selected tetranucleotide repeat